A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+ NON‐HODGKIN'S LYMPHOMA. (June 2017) - Gopal, A.; Levy, R.; Houot, R.; Patel, S.; Hatake, K.; Popplewell, L.; Chen, Y.; Davis, C.; Huang, B.; Cesari, R.; Thall, A.; Woolfson, A.; et al.